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Abstract
The primary limitation of magnetic drug targeting (MDT) relates to the strength of an external magnetic field which
decreases with increasing distance. Small nanoparticles (NPs) displaying superparamagnetic behaviour are also
required in order to reduce embolization in the blood vessel. The small NPs, however, make it difficult to vector NPs
and keep them in the desired location. The aims of this work were to investigate parameters influencing the capture
efficiency of the drug carriers in mimicked arterial flow. In this work, we computationally modelled and evaluated
capture efficiency in MDT with COMSOL Multiphysics 4.4. The studied parameters were (i) magnetic nanoparticle size,
(ii) three classes of magnetic cores (Fe3O4, Fe2O3, and Fe), and (iii) the thickness of biocompatible coating materials
(Au, SiO2, and PEG). It was found that the capture efficiency of small particles decreased with decreasing size and was
less than 5 % for magnetic particles in the superparamagnetic regime. The thickness of non-magnetic coating
materials did not significantly influence the capture efficiency of MDT. It was difficult to capture small drug carriers
(D < 200 nm) in the arterial flow. We suggest that the MDT with high-capture efficiency can be obtained in small
vessels and low-blood velocities such as micro-capillary vessels.
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Background
In magnetic drug targeting (MDT), magnetic nanoparti-
cles (MNPs) coated with therapeutic agents are injected
into the blood vessels. Then they are vectored to spe-
cific targets by an externally applied magnetic field. This
allows therapy to be concentrated in abnormal tissues
while keeping therapeutic concentrations low thus reduc-
ing side effects. This can be therefore useful for treatment
of cancer [1], atherosclerosis [2], arterial occlusion, stroke,
and other diseases.
Magnetically responsive drug carriers can be mag-
netite (Fe3O4) or maghemite (Fe2O3). Their properties
are related to their size. As the particle size decreases
toward some critical diameter (Dc) the formation of
domain walls becomes unfavourable, and the particles
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are called single domain. A nanoparticle displays super-
paramagnetic behaviour once its size is smaller than the
critical diameter [3]. That is, it exhibits net magnetiza-
tion only in the presence of an external magnetic field.
This allows nanoparticles (NPs) to travel freely through-
out the circulatory system until they are in the presence
of the magnetic field, which then acts to trap the NPs at
the defined location. After removing the magnetic field,
the NPs lose their previously induced magnetization thus
reducing embolization in the blood vessel.
Table 1 summarizes the single-domain size of spherical
particles for some common materials. They are single-
domain over the size range of approximately 10–130 nm.
Particles in this range are of particular interest tomagnetic
drug targeting. It is worth noticing that the single-
domain size in Table 1 shows some large discrepan-
cies between references [3–7], especially in magnetite.
Magnetite phases may show peculiar hysteresis properties
when the particle size is decreased. However, an estimate
© 2015 Lunnoo and Puangmali. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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Table 1 Single-domain size for the MNPs below for which the
material will not support a multi-domain particle
MNPs Single domain size (nm) Reference
Fe3O4 128 Ref. [3]
83 Ref. [4]
20–29 Ref. [5]
20–30 Ref. [6, 7]
Fe2O3 166 Ref. [3]
91 Ref. [4]
Fe 14 Ref. [3]
of single-domain size from hysteresis measurements
[6, 7] may thus be misleading. Furthermore, critical size
estimates may be more reliable if they are deduced from
magnetic studies on pure magnetite samples containing
a narrow range of particle sizes rather than a large size
variation.
Fe nanoparticle is another choice for MDT [8]. It can
be readily synthesized with superior magnetic proper-
ties. Nonetheless, it is not biocompatible and, typically,
Fe NPs are not suitable for in vivo applications. One
strategy would be to take advantage of their superior
magnetic properties and enhanced hyperthermia at con-
centrations low enough to be nontoxic. Alternatively, a
core/shell strategy to mitigate their toxicity needs to be
explored. Core/shell nanomaterials are extremely impor-
tant as they can have a combination of different properties
and offer multifunctionality because core and shell can
have different material compositions in a single particle.
The life-time of MNPs in the circulatory system is
another important factor for MDT. It depends upon their
size and structure. As shown in Fig. 1, the magnetic core
of the drug carrier is typically coated by a biocompatible
material such as gold (Au), polyethylene glycol (PEG), or
silica (SiO2) [9, 10]. The coating layer acts to shield the
magnetic particle. For example, a gold layer coated on an
Fe3O4 core serves two key purposes [11]. First, it prevents
oxidation of the Fe3O4 core into maghemite by forming an
inert biocompatible protective coating. Second, it forms
an excellent platform for conjugating drugs onto nanopar-
ticle surfaces, since gold has a natural affinity for thiol
bonds.
The primary limitation ofMDT relates to the strength of
the external magnetic field [12] as the magnetic gradient
decreases rapidly with increasing distance to the target.
A magnetic field must be applied to obtain the neces-
sary magnetic gradient to control the residence time of
NPs in the desired area. As a means to overcome limita-
tions of using external magnetic fields, implant magnets
[13] or ferromagnetic microwires [14] can be located in
the vicinity of the target using minimally invasive surgery.
Several studies [15, 16] have simulated the interaction
between magnetic implants and magnetic NPs, enabling
drug delivery. Another limitation relates to the small size
of NPs, a requisite for superparamagnetism, which is
needed to avoid embolization once the magnetic field is
removed. Nonetheless, a small size implies a magnetic
response of reduced strength. This makes it difficult to
magnetically direct drug-loaded particles and keep them
in the proximity of the target while withstanding the drag
force of blood flow. MDT is likely to be more effective
in lower blood velocities, particularly when the magnet
is close to the target site. In addition, most intravenously
applied NPs are recognized as “foreign” by the body sys-
tem. They are immediately eliminated by macrophages
of a mononuclear phagocytosis system (MPS). Generally,
smaller NPs are subject to rapid elimination while larger
ones show uptake by the liver, spleen, and bone marrow
[17]. Based on the biokinetics of the particles, a drug-
loaded carrier size range of approximately 10–200 nm in
diameter is optimal for in vivo delivery, as the small par-
ticles (D < 10 nm) escape by renal clearance [18] and the
large ones (D > 200 nm) are quickly eliminated by the
reticuloendothelial system (RES) of the spleen and liver
[18], as illustrated in Fig. 1.
The aims of this work were as follows. Firstly, the size-
dependent capture efficiency of Fe3O4, Fe2O3, and Fe NPs
inmimicked arterial flow was computationally studied. As
the carrier size range of approximately 10–200 nm is opti-
mal for in vivo delivery, the magnetic nanoparticle size
in this range was particularly of interest. No theoretical
work has so far been published on the analysis of particle
size in the superparamagnetic scale as shown in Table 1.
Most theoretical studies [2, 19–25] were carried out in the
particle size range of 250–4 μm. In fact, large particles
are eliminated by the reticuloendothelial system, and they
have short life-time [17] in the cardiovascular system. Sec-
ondly, the effects of three different coating layers upon the
capture efficiency of MDT were investigated. The coat-
ing layers were Au, PEG, and SiO2. Lastly, a drug carrier
structure that is suitable for MDT is introduced.
Methods
The two-dimensional model geometrical representation
of the artery with a permanent magnet is used in our
model. It was assumed that the variation in transport of
magnetic nanoparticles under the influence of magnetic
field will be very small in the direction perpendicular to
the x-y plane (see Fig. 1) because of a high aspect ratio of
cross-sectional geometry that is modelled, compared with
the size of a nanoparticle [26]. Moreover, a 2D model will
serve as a simple, fast, and relatively accurate guideline for
designing and optimizing the capture efficiency in MDT.
The two-dimensional model for MDT is illustrated
in Fig. 2. A stationary magnetic field produced by a
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Fig. 1 Drug-loaded carrier is typically composed of a magnetic core and a biocompatible coating material. The magnetic core was made from
different materials such as Fe3O4, Fe2O3, or Fe. The coating materials are Au, PEG, or SiO2. Based on the biokinetics of particles, a drug carrier ranging
from 10–200 nm in diameter is optimal for in vivo delivery, as the small particles (D < 10 nm) escape by renal clearance [18] and the large ones
(D > 200 nm) are sequestered by the reticuloendothelial system of the spleen and liver [18]
permanent magnet implanted at a specific location is
described by the following equations:
Ampère’s law
∇ × H = J, (1)
Gauss’s law for the magnetic flux density
∇ · B = 0, (2)
and the magnetic flux density in different domains can be




μ0μr,magH + Brem magnet (domain 1)
μ0(H + Mb(H)) blood (domain 2)
μ0H air and tissue (domain 3)
(3)
whereH is the magnetic field strength (A/m), J is the cur-
rent density (A/m2) and B is the magnetic flux density
(T), μ0 = 4π × 10−7 N/A2 is the magnetic perme-
ability of air, μr,mag is the relative permeability of the
permanent magnet, Brem is the remanent magnetic flux
density (A/m), and Mb(H) is the magnetization vector of
the blood stream (A/m), which is a function of magnetic
field,H.
For the blood in domain 2, defining a magnetic vector
potential A such that
B = ∇ × A and ∇ · A = 0, (4)
it can be shown that:
B = ∇ × A = μ0(H + Mb), (5)
1
μ0
(∇ × A) = H + Mb, (6)
H = 1
μ0
(∇ × A) − Mb. (7)




∇ × A − Mb
)
= J. (8)
It is assumed that the magnetic vector potential has a
non-zero component perpendicular only to the plane Az,
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Fig. 2 The two-dimensional model which is a representative for arterial flow. Domain (1) represents an implanted Nd-B-Fe magnet with a maximum
field strength of B = 2 T as reported in Takeda and co-workers [44] while domain (2) and (3) are blood vessel and vessel wall of the artery. Various
numerical grids in different domains are generated. The maximum element sizes for numerical mesh in domains (1), (2), and (3) were 0.083, 0.020,
and 0.153 cm, respectively
which basically simplifies the 2D and it has perpendicular





∇ × A − Mb
)
= 0. (9)
Induced magnetization of the blood, Mb(x, y), can be

















where α (A/m) and β (m/A) are ferrofluid magnetization-
curve parameters. The material parameters α and β are
obtained using M-H curve from the literature, and they
are assumed to be constant for a range of magnetic
nanoparticles 10–1000 nm in radius [28]. It was also
assumed that the magnetic nanoparticles do not interact
in the surrounding fluid. According to Taylor polynomial









where χ = αβ is the magnetic susceptibility.
The flow of an incompressible non-Newtonian fluid
(blood) is described by the Navier-Stokes equation. The
relative importance of inertial forces compared to viscous
forces is given by the dimensionless Reynolds number
Re = ρbv0l/η with v0 and l characteristic velocity and
length scales of the blood flow under consideration. For
the current study, blood density ρb = 1, 060 kg/m3, the
average blood velocity [23] v0 ≈ 10 cm/s, blood vessel
diameter [23] l ≈ 3mm, and dynamic viscosity of blood
η ≈ 3.5× 10−3 kg/(m.s), the Reynolds number Re ≈ 121,
which is well within the laminar flow regime. When the
Reynolds number is low, the Navier-Stokes equation is
ρb
∂ub
∂t + ρbub · ∇ub = −∇p + η∇
2ub + FV (14)
where ub is blood velocity, p is the pressure, and FV is
the volume force (N/m2). The momentum transfer from
MNPs to the fluid is incorporated by setting the volume
force term equal to the magnetic force and the drag force.
This term couples the fluid flow equation with the static
magnetic field equation.
There are several models explaining the rheology of
blood. The comparison of five non-Newtonian models for
blood viscosity as well as a Newtonian model in the flow
simulation were considered by Johnson and colleagues
[29]. Given the discussion and results in Ref. [29], it was
concluded that the Generalised Power Law model [30] fit-
ted the experimental stress-strain measurements over the
wide range of strain rates (γ˙ ), 0.1 < γ˙ < 1000 s−1. The
Generalised Power Law model, in addition, also encapsu-
lates the behaviours of many of the other blood models.
It is Newtonian [29] at high strain rates and behaves like
the Power Law model [31] at low strain rates. Moreover,
it has Casson [32] and Carreau [31] models as special
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cases. Therefore, the rheology of blood in our model was
described using a generalized power law model [30]
η = λ(γ˙ )|γ˙ |n(γ˙ )−1 (15)






















where |γ˙ | is the magnitude of the strain rate. The val-
ues used in our model were adapted from the work of
Ballyk and co-workers [30]: η∞ = 0.0035 kg/(m.s), η =
0.025 kg/(m.s), a = 50 s−1, b = 3 s−1, n∞ = 1, n =
0.45, c = 50 s−1, and d = 4 s−1.
During the motion of MNPs in the circulatory sys-
tem, there are several forces acting upon magnetic par-
ticles in viscous environments and magnetic fields. This
includes magnetophoretic forces due to external mag-
netic fields, Stokes’s viscous drag force, Brownian force,
buoyancy and gravity, inertia, and particle fluid interac-
tions. Apart from magnetophoretic forces, Brownian and
viscous drag forces, other interactions are negligible for
magnetic micro- or nanoparticles. Brownian forces act-
ing upon particle motion were considered in our model.
This is due to the fact that Brownian motion and the
corresponding stochastic forces significantly influence the
dispersion of small particles (with d ≤ 50 nm) [33, 34].
Taking these forces into account, the trajectories and




dt2 = FM + FD + FB. (18)
The first term on the right-hand side of Eq. (18) is the
magnetophoretic force (FM) while the second and the
third terms account for the drag force (FD) and Brownian
force (FB), respectively.
Magnetophoresis is the motion of particles with respect
to a surrounding medium caused by the net interaction of
a magnetization with a magnetic field gradient. Magne-
tophoretic force FM on a particle [35] is given by
FM = (μbmeff · ∇)H (19)
whereH is the external magnetic field, μb is the magnetic
permeability of the blood, and meff is the magnetic dipole
moment induced by the field. If we assume that particles
respond linearly to the magnetic field, for spherical par-
ticles with radius r the magnetophoretic force [35] in a
steady magnetic field is given by
FM = 2πμbr3K∇|H|2 (20)
where
K = μp − μb
μp + 2μb . (21)
Subscripts b and p indicate blood and particle, respec-
tively.K is the Clausius-Mossotti factor whose value range
is−0.5 ≤ K ≤ 1.0. It provides a measure of the magnitude
of the magnetophoretic force and its direction. It is called
the negative magnetophoretic force if the permeability of
the blood is larger than that of the particle. It is interest-
ing to note that the magnetophoretic force is proportional
to permeability of the suspension medium, the gradient
of the magnetic field intensity and particle radius. Addi-
tionally, it is important to note that in our calculation it is
assumed that captured nanoparticles do not influence the
local magnetic field gradient.
For a particle (Rep ≡ ρp|up − ub|D/η  1) having
a Reynolds number so low that viscous forces dominate
over inertial forces, as in generally the case for the situa-
tion studied in this work, the drag force FD on spherical









τ is the particle relaxation time, ub and up are blood and
particle velocity, respectively.
The Brownian force was incorporated into the equation






where kB is the Boltzmann constant (kB = 1.38 × 10−23
J/K), T is the absolute temperature, and t is the magni-
tude of time step. The parameter ζ is a Gaussian random
number with zero mean and unit variance. The random
direction of the Brownian force was accounted for by eval-
uating both the x and y components of FB at each time
step using independent values of ζ in both dimensions.
From a magnetic drug targeting point of view, a major
challenge is to create a large enough magnetic force to
capture drug-loaded carrier of a reasonably small size. To
optimize the capture efficiency (ε) of magnetic drug tar-
geting, the class of magnetic core and coating materials
must be considered. The capture efficiency for a length of
artery is defined as the fraction of magnetic nanoparticles







where εin and εout are the number of particles entering and
leaving the section of artery, respectively.
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The aim of our model was to mimic a more realistic
situation of arterial flow, but still in a relatively sim-
ple and well-defined geometry, as illustrated in Fig. 2.
Various numerical grids in different domains were gener-
ated. The maximum element size for numerical mesh in
domains (1), (2), and (3) were 0.083, 0.020, and 0.153 cm,
respectively. The waveform of the arterial blood flow for a
reduced artery geometry was obtained by fitting a piece-
wise polynomial with experimental data [38]. The studied
geometry included only one main inlet artery (Dinlet ≈
4 mm) and seven outlets (Doutlet ≈ 0.4 – 1.5mm). The
model was characterized by two basic features occur-
ring in blood flow during magnetic drug targeting: blood
velocity profile in the artery and a non-uniform magnetic
field. A schematic representation of the setup is shown in
Fig. 2.
Magnetic nanoparticles were homogeneously injected
at the main inlet and their trajectories were calculated
by solving Eq. (18). Different sizes of nanoparticles were
considered, starting from 10 nm to 2 μm in radius. It
is notable that the upper limit for the particle radius
(rmax = 2μm) was determined by the characteristic size
of the micro-capillary vessel. Recently, Alexiou and co-
workers [13] treated squamous cell carcinoma in rabbits
with ferrofluids bound to mitoxantrone (FF-MTX) that
was concentrated with a magnetic field. FF-MTX was
injected intraarterially (femoral artery). It was suggested
by their preclinical experiment that the FF-MTX con-
tained 6.5 mg ofMTX per 10ml. The ferrofluids consisted
of iron content (D ∼ 100 nm) roughly 30 mg Fe/ml (the
number of particles ∼ 1010/ml). In the present model, a
length of artery was studied; thus, we assumed that only
6000 magnetic nanoparticles were inserted into the arte-
rial flow (domain 2 in Fig. 2). In order to be able to average
a flow cycle, they were homogeneously distributed over
the inlet at consecutive time intervals of t = 0, 0.01,
0.02, 0.03, 0.04, and 0.05 s. The effective concentration of
nanoparticles is approximately 3.15 × 10−6 mg Fe/ml.
In the human blood vessel the surface of endothelium is
lined with a glycocalyx, a layer membrane bound macro-
molecules and adsorbed proteins. Physically, this layer is
highly negatively charged [24], which interact with the
moving plasma (treated as an electrolyte). Thus, the pres-
ence of the glycocalyx would possibly cause an increase in
flow resistance. Pries and co-workers [39] reported that
the glycocalyx layer is capable to impede plasma flow,
which is probably due to high negative charge. However,
Sugihara-Seki and Fu [40] suggested that the increase in
flow resistance would be negligible if the glycocalyx is
thin compared to the vessel diameter. Several electron
microscopy studies [41] indicate the presence of the gly-
cocalyx in the human blood vessel with a thickness of
less than 100 nm, which is much thinner than the stud-
ied artery diameter (0.4 cm). The exact interaction [42]
of magnetic particles with the endothelial lining is much
more complicated than such a simple boundary condition
does justice to. However, Haverkort and colleagues [2]
showed that specific boundary conditions did not strongly
influence the results. Therefore, in the present simulation,
the particles were assumed to elastically collide with the
arterial wall during the motion in the blood stream.
Three different magnetic cores were comparatively
studied including Fe3O4, Fe2O3, and Fe. Their magnetic
properties are shown in Table 2. In addition to the mag-
netic core, the thickness-dependent effect of three differ-
ent coating layers (Au, SiO2, and PEG) was also carried
out. The shell thickness was varied from 5–50 nm. The
densities of Au, SiO2 and PEG were 19,320, 2648 and
1114 kg/m3, respectively. Once the core/shell structure
was considered, the magnetophoretic force (FM) acting
upon the particle was due exclusively to the magnetic core
whereas the whole volume (core and coating layer) was
taken into account for Stokes drag force (FD). The mag-
netic field originates from the implanted magnet (domain
1 in Fig. 2). The blood vessel and the vessel wall were in
domains 2 and 3. The magnetic field in all domains was
calculated by Eq. (1–3). The capture efficiency, defined
in Eq. (25), was comparatively studied for the magnetic
nanoparticles ranging from 10 nm-4 μm in radius.
All calculations in the present work were performed
in COMSOL Multiphysics 4.4. For implementing the
model, the following interfaces were initially required: (1)
CFD module involving sophisticated blood flow models;
(2) AC/DC module used for generating magnetic fields,
and (3) particle tracing module which is capable of simu-
lating particle trajectories in the blood stream. This pack-
age allowed the two-dimensional geometry of the artery
and an implanted Nd-B-Fe magnet illustrated in Fig. 2 to
be constructed. The governing equations used to simulate
magnetic fields, non-Newtonian blood flow, and parti-
cle trajectories were Eq. (3), (14), and (18), respectively.
Table 2 Parameter values and properties of the materials used in
this work. Note that ρ is density, η is dynamic viscosity, and χ is
magnetic susceptibility,
Materials Properties Value Unit
Blood ρb 1060 kg/m3
ηb 0.0035 kg/(m.s)
χb −6.6 × 10−7 -
Fe3O4 χ 3.1 -
ρ 5230 kg/m3
Fe2O3 χ 2.5 -
ρ 4890 kg/m3
Fe χ 3.9 -
ρ 7760 kg/m3
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User-defined functions were written to implement the
viscosity model of Eq. (15–17) and the particle magne-
tophoretic force of Eq. (20). Last but not least, the capture
efficiency was evaluated by Eq. (25).
Results and discussion
Blood flow
After a steady-state simulation was calculated for themag-
netic field in all domains, transient simulations based on
the Navier-Stokes equation were performed for the arte-
rial flow. Each cardiac cycle was from t = 0 to t = 1.00 s,
yielding a heart rate of approximately 60 beats per minute.
At the inlet, the shape of the velocity profile is a plug flow.
The blood flow was observed for 5 s. Contours of the
blood velocity along the artery are shown in Fig. 3. The
main inlet is marked with a red arrow. The physiologi-
cal waveform used in this study was based on the work of
Matsuo and co-workers [38], whomeasured the waveform
in healthy patients using a Doppler flow meter catheter.
The velocity profile, obtained by digital extraction from
Ref. [38] and fitting extracted data with a polynomial of
degree 9, is illustrated in Fig. 3 (top). The flow pattern in
the arterial flow is characterized by a small forward flow
during systole (S wave) with a large forward flow during
diastole (D wave). In this particular case, the peak of the
S wave is just below half of the D wave. It is notable that
(a) t = 0 s is the beginning of each cardiac cycle, just prior
to the deceleration of the blood flow, (b) t = 0.12 s is the
point of maximum reverse velocity, (c) t = 0.35 s is the
peak of the S wave, (d) t = 0.50 s is halfway through the
rapid acceleration phase and (e) t = 0.85 s is the point of
maximum forward velocity, the peak of the D wave. An
essential aspect of the structure of the artery is its charac-
teristic curve. For a given section of the artery structure,
there occur differences, often significant, in inner diame-
ters (left to right), and thus in flow fields. Such variations
in inner diameters do not exceed the range of 2–6 mm. As
shown in Fig. 3 (bottom), the inner diameter of the inlet
(right) is Dinlet = 0.40 cm. The inner diameters of the
branches (from right to left) are 0.15, 0.04, 0.11, 0.08, 0.10,
0.10, 0.10 cm, respectively. The asymmetrical distribution
of the velocity profile shown in Fig. 3 (bottom) is due to
the anatomical differences between the left and the right
sides of the artery.
To portray complex flow patterns, the blood flow
coloured by velocity magnitude in the blood vessel are
shown in Fig. 3 (bottom). Side-by-side comparison of the
velocity waveform and velocity contour plot at charac-
teristic locations can be made. Figure 3 shows a rep-
resentative data set of the velocity in the artery using
Fig. 3 (Top) The physiological waveform used in this study was based on the work of Matsuo and co-workers [38], measured by means of a
bidirectional Doppler flow meter catheter. (Bottom) The inner diameter of the inlet (right) is Dinlet = 0.40 cm. The velocity magnitude (represented
by colour bar) in the simulated arterial flow corresponds to the velocity profile illustrated in the top figure. The red arrows denote the direction of
flow at the inlet
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the Generalised Power Law blood viscosity model [30].
Velocity magnitudes are shown at times, t = 0, 0.12, 0.35,
0.44, 0.50, 0.62, 0.85, and 1.00 s through the cardiac cycle.
These values were chosen as they are representative of
key points during the cardiac cycle. It can be seen from
Fig. 3 (top) that the minimum and maximum values are
located at t = 0.12 s and t = 0.85 s, in accordance with the
contour plots shown in Fig. 3 (bottom).
Particle trajectory
In order to mimic targeted drug delivery, an externally
implanted superconductive magnet was introduced. The
origin, orientation, and strength of the imposed mag-
netic field can be easily manipulated to cover the desired
location. As can be seen from Fig. 4, the magnetic field
strength rapidly decreased with increasing distance from
the magnet. At the target location, the average magnetic
field strength was approximately 0.5 T and the gradient
of the magnetic field at the vessel centre is 1.80 T/cm.
The distribution of particles along the arterial vessel is
also shown in Fig. 4. The velocity magnitude of drug
carrier is represented by their colours. Red represents
particles moving at high velocity whereas low velocity
is coded by blue. There are large holes in the particle
cloud near the centre of the artery model (particularly
near t = 0.27 s and t = 0.32 s). The large holes in
the particle cloud near the centre of the artery are due
to the fact that MNPs were distributed over the inlet
at consecutive time intervals of t = 0, 0.01, 0.02, 0.03,
0.04, and 0.05 s. In addition, at the inlet, the shape of
the velocity profile is a plug flow. It can be clearly seen
that the particles were more concentrated at the arte-
rial wall near the externally magnetic field source while
other regions remained free of the magnetic nanopar-
ticles, confirming enhanced deposition due to imposed
magnetic field.
Fig. 4 The distribution of particles (rp = 2 μm) after the first injection at (a) t = 0.27 s, (b) t = 0.32 s, (c) t = 0.40 s, (d) t = 0.45 s, (e) t = 0.50 s,
(f) t = 1.08 s. The magnetization vectors are shown by the white arrows. The magnetic flux density and the velocity magnitude of the particles are
represented by the colour contour. It is worth noting that the particles leaving the first branch were not included in the capture efficiency calculation
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Particle capture
To introduce a more objective qualification of the parti-
cle capturing, the contour of the local particle deposition
for rp = 2μm class of particles is illustrated in Fig. 4. It
can be seen that for the magnetically active case, MNPs
were captured at the target site. Figure 5 shows the calcu-
lation result for the capture efficiency (ε) of magnetic drug
targeting in the simulated arterial flow as a function of
core size. The size-dependent capture efficiency of Fe3O4,
Fe2O3, and Fe nanoparticles (rp = 10–4000 nm) in mim-
icked arterial flow was comparatively studied. The first
observation from Fig. 5 is that bigger particles have better
total cumulative capturing efficiency compared to smaller
particles. This is what was theoretically expected as the
magnetophoretic force increases as FM ∝ r3 (as shown
in Eq. (20)). For particles bigger than 2μm in radius, high
capture efficiencies of 90–95 % were observed. However,
the upper limit for the particle diameter is determined
by the characteristic size [43] of the micro-capillary ves-
sel (Dcapillary ≈ 4μm). Therefore, we are particularly
interested in particle sizes below this characteristic size.
As mentioned in the introduction, a carrier size of
10–200 nm in diameter is appropriate for in vivo deliv-
ery since larger particles (D > 200 nm) are eliminated by
the reticuloendothelial system, and they also have short
life-time [17] in the cardiovascular system whereas the
small particles (D < 10 nm) escape by renal clearance
[18]. Additionally, carrier sizes of 10–200 nm in diame-
ter displays superparamagnetic behaviour thus reducing
embolization when the external magnetic field source is
removed. However, the capture efficiency of the drug car-
rier in nanoscale regime is relatively low, as shown in the
inset of Fig. 5. It is clear that only a small fraction of par-
ticles is captured at the moment when the particles flow
for the first time past the implanted magnet. However,
the particles will flow by the magnet again, as they cir-
culate continuously in the bloodstream. Thus, the overall
capture efficiency, in the limit of many passes, could be
much higher than the value shown in Fig. 5. Nonethe-
less, there are biological processes competing with the
magnetic capture process, and this means that the over-
all capture efficiency will be smaller than otherwise. For
particles with 50 nm in radius, 3251 nanoparticles passed
through the magnetic field and only 60 particles were cap-
tured (capture efficiency = 1.85%) at the desired location.
This small capture efficiency is due to the small magne-
tophoretic force. The Stokes drag force also dominates in
the small particles due to high blood velocity compared
to the blood velocity in smaller vessels. Apart from this,
Brownian motion and the corresponding stochastic force
significantly influence the dispersion of the small particles
(with d ≤ 50 nm) [33, 34]. The fluctuation of capture effi-
ciency shown in the inset of Fig. 5 is due particularly to the
Brownian motion of small particles.
From a drug-targeting application point of view, we
focused on a more detailed analysis of different classes
of core/shell structures with different shell thicknesses.
The capture efficiency of the core/shell structure is depen-
dent upon the size of the magnetic core. Results shown
in Fig. 5 can also be seen in Fig. 6. It is notable that coat-
ing Fe3O4 nanoparticles with different classes of materials
(Au, SiO2, and PEG) did not significantly influence the
capture efficiency. Once a magnetic particle is passivated
by biocompatible materials (non-magnetic materials), the
magnetophoretic force (FM) is not changed compared
with the particle without passivation. In summary, the
coating layer thickness did not significantly influence
the capture efficiency of magnetic drug targeting as
shown in Fig. 6. Similar results were found in the Fe2O3
and Fe nanoparticles.
Fig. 5 The capture efficiency (ε) of magnetic drug targeting in the simulated arterial flow as a function of core size. The upper limit for the particle
radius was determined by characteristic size of the micro-capillary vessels (rmax = 2μm). The inset shows the efficiency of MDT in the nanoscale
regime (10–100 nm)
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Fig. 6 The capture efficiency (ε) of Fe3O4 nanoparticles coated with
three different biocompatible materials including Au, PEG, and SiO2.
The thickness of coating materials was varied from 5–50 nm. The
capture efficiency of two magnetic core sizes is compared. Note that
black squares and red triangles represent the core size 50 and 500 nm
in radius, respectively
Conclusions
The size-dependent capture efficiency of Fe3O4, Fe2O3
and Fe NPs in mimicked arterial flow was computation-
ally studied. Carrier sizes of 10 nm-4μm in radius were
considered. Particles larger than 2μm were efficiently
captured at the desired location by the external mag-
netic field, and the capture efficiency was approximately
95 %. However, particle sizes in this region are not suit-
able for in vivo delivery as larger particles are eliminated
by the reticuloendothelial system, and they also have short
life-times [17] in the cardiovascular system. The suitable
size is 10–200 nm in radius, but the capture efficiency
of small particles decreased with decreasing size. It was
found that the capture efficiency of small particles in arte-
rial flow was less than 5 %. This is due to the reduced
magnetophoretic force with decreasing size. Additionally,
coating the NPs with different classes of non-magnetic
materials (Au, SiO2, PEG) did not significantly influence
the capture efficiency of MDT. In light of this, we propose
that the magnetic drug targeting with high-capture effi-
ciency will be obtained in small vessel and low blood
velocity such as micro-capillary vessels.
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